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Phase Ib/II single-arm trial evaluating the 
combination of everolimus, lapatinib and 
capecitabine for the treatment of  
HER2-positive breast cancer with brain 
metastases (TRIO-US B-09)
Sara Hurvitz, Rashi Singh, Brad Adams, Julie A. Taguchi, David Chan, Robert A. Dichmann, 
Aurelio Castrellon, Eddie Hu, Jonathan Berkowitz, Aruna Mani, Brian DiCarlo,  
Rena Callahan, Ira Smalberg, Xiaoyan Wang, Ivana Meglar, Diego Martinez,  
Evthokia Hobbs and Dennis J. Slamon
Abstract
Background: Improving outcomes for patients with human epidermal growth factor 2-positive 
(HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This trial 
evaluated a novel combination of everolimus, lapatinib and capecitabine for this disease.
Methods: Patients with trastuzumab-pretreated, HER2+ breast cancer brain metastasis 
without prior therapy with a mammalian target of rapamycin (mTOR) inhibitor were eligible. 
Patients received lapatinib and everolimus daily (continuously) and capecitabine twice daily 
(d1–14) in 21-d cycles. The primary endpoint was the 12-week CNS objective response rate 
(ORR). Secondary endpoints included safety, progression-free survival (PFS), overall survival 
(OS), best CNS ORR and extra-CNS ORR.
Results: A total of 19 participants were enrolled and treated with ⩾1 dose of the study drug. 
The median age was 58.5 years, the median number of therapies for metastatic breast 
cancer was 2.5 (0–11). Pretrial, 74% of participants had received prior lapatinib, capecitabine 
or both. A total of 63% had received previous CNS radiation or surgical resection and CNS 
radiation. The maximum tolerated doses were lapatinib at 1000 mg, everolimus at 10 mg, 
and capecitabine at 1000 mg/m2. Phase II proceeded with capecitabine at 750 mg/m2 due 
to better tolerability. The most common grade 3/4 adverse events were mucositis (16%), 
diarrhea, fatigue, and hypokalemia (11% each). Of 11 participants evaluable for 12-week 
CNS ORR, 3 (27%) had partial response and 7 (64%) had stable disease. The best CNS ORR 
in eligible participants was 28% (5/18). The median PFS and OS were 6.2 and 24.2 months, 
respectively.
Conclusions: This novel triplet combination of lapatinib, everolimus, and capecitabine is 
well tolerated and yielded a 27% response rate in the CNS at 12 weeks in heavily pretreated 
participants. Larger studies are warranted to further evaluate this regimen.
Trial registration: ClinicalTrials.gov: NCT01783756. Registered 05 February 2013, https://
clinicaltrials.gov/ct2/show/NCT01783756
Keywords: capecitabine, chemotherapy, everolimus, HER2+ breast cancer, lapatinib, 
metastatic brain tumors, PI3K/Akt/mTOR inhibitor, tyrosine kinase inhibitor
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Introduction
While trastuzumab has dramatically improved 
outcomes for patients diagnosed with human epi-
dermal growth factor 2-positive (HER2+) breast 
cancer1–5 its use has not resulted in a lower inci-
dence rate or substantial responses in central 
nervous system (CNS) metastases, likely owing to 
the fact that the blood–brain barrier prevents the 
entry of large antibodies.6,7 A phase II trial evalu-
ating the HER1/HER2 inhibitor, lapatinib8 for 
patients with progressive breast cancer brain 
metastases (BCBM) after radiation and trastu-
zumab demonstrated a 6% objective response 
rate (ORR) in the CNS and a progression-free 
survival (PFS) of 2.4 months. In an extension 
phase of this study, 50 patients whose disease 
progressed on lapatinib were treated with lapat-
inib plus capecitabine. Of these, 20% achieved a 
CNS partial response (PR) and the median PFS 
was 3.65 months.
Everolimus (RAD001) selectively inhibits the 
mammalian target of rapamycin (mTOR), a highly 
conserved kinase that acts as a central regulator of 
protein synthesis, cell growth, proliferation, angio-
genesis and survival through the phosphoinositide 
3-kinase (PI3K) signaling pathway.9–12 Everolimus 
is United States Food and Drug Administration 
(US FDA)-approved in combination with exemes-
tane for patients with hormone receptor (HR)-
positive HER2-negative advanced breast cancer, 
previously treated with a nonsteroidal aromatase 
inhibitor.13 The mTOR pathway has been impli-
cated as a mechanism of resistance to HER2-
targeted therapy. Preclinical data from our 
laboratory also suggest that everolimus has activity 
in HER2+ breast cancers.14 The phase III 
BOLERO-3 trial demonstrated a modest improve-
ment in PFS when everolimus was added to trastu-
zumab and vinorelbine in patients with heavily 
pretreated HER2+ advanced breast cancer.15 
Importantly, murine models indicate significant 
penetration of everolimus into the CNS.16
A phase I clinical trial in patients with advanced 
cancers evaluated lapatinib plus everolimus and 
defined 1250 mg of lapatinib and 5 mg of everoli-
mus daily as the maximum tolerated dose 
(MTD).17 Additionally, two phase I studies have 
demonstrated the safety and activity of capecit-
abine combined with everolimus. The MTDs for 
capecitabine and everolimus were 1000 mg/m2 
twice daily and 10 mg once daily, respectively in 
one study18 and 650 mg/m2 twice daily and 5 mg 
twice daily, respectively in the other study.19
We initiated an investigator-initiated phase Ib/II 
multicenter clinical trial to explore the safety and 
activity of a novel triplet combination of lapat-
inib, everolimus and capecitabine for patients 
with progressive HER2+ BCBM.
Methods
Study design and patient eligibility
TRIO-US (Translational Research in Oncology-
United States) B-09 is an open-label, multicenter, 
phase Ib/II single-arm study evaluating the com-
bination of everolimus, lapatinib and capecit-
abine. Eligible participants included women 
⩾18 years with locally-confirmed HER2+ [IHC 
3+ or amplified by fluorescence in-situ hybridiza-
tion (FISH)]20 metastatic breast cancer (MBC) 
previously treated with trastuzumab. Documented 
progression of disease (PD) in the brain (⩾1 CNS 
lesion ⩾10 mm) was required after the most 
recent therapy. Any number of prior systemic 
regimens were allowed as long as participant had 
recovered from grade ⩾2 side effects per National 
Cancer Institute/National Institutes of Health 
Common Terminology Criteria for Adverse 
Events (NIH-NCI CTCAE version 4.03).21 Prior 
therapy with lapatinib or capecitabine was 
allowed. Lapatinib must have been discontinued 
at least 14 days prior to starting study treatment 
and previous chemotherapy (including capecit-
abine) must have been discontinued at least 
21 days prior to starting study treatment. 
Concurrent steroids up to an equivalent of 20 mg 
prednisone daily, on taper or stable dose for 
⩾2 weeks was allowed. Adequate hematologic, 
renal, and hepatic function were required. 
Participants were required to have an Eastern 
Cooperative Oncology Group (ECOG) perfor-
mance status of ⩽2 with a life expectancy of 
⩾12 weeks.22 Prior treatment with an mTOR 
inhibitor, leptomeningeal carcinomatosis as the 
only site of CNS disease, active noncancer-related 
hepatic or biliary disease, clinically significant 
interstitial lung disease or history of cardiac dis-
ease were exclusionary.
All participants provided written informed con-
sent prior to enrollment. The protocol and 
informed consent were approved by the Johnson 
Comprehensive Cancer Center (JCCC) Office of 
Regulatory Compliance at UCLA (IRB# 
12-001358) and by Western-IRB. This is an 
investigator-sponsored trial by TRIO-US and 
pharmaceutical sponsors, Novartis and GSK.
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Study treatment
All drugs were self-administered orally over 
21-day cycles. Everolimus and lapatinib were 
given once daily continuously and capecitabine 
twice daily on days 1–14.
An initial 3+3 dose-escalation phase of the study 
was conducted to evaluate the safety of this com-
bination. Lapatinib was given at a fixed dose of 
1000 mg daily. Dose escalation of capecitabine 
and everolimus were as follows: cohort 1: capecit-
abine 750 mg/m2, everolimus 5 mg; cohort 2: 
capecitabine 750 mg/m2, everolimus 10 mg; 
cohort 3: capecitabine 1000 mg/m2, everolimus 
10 mg. Dose reductions for each drug in each 
cohort were permitted for toxicity. Dose-limiting 
toxicities (DLTs) were assessed during the first 
cycle of treatment and defined as NIH-NCI 
CTCAE version 4.03 grade 3/4 treatment-related 
toxicity lasting more than 1 week.21 The dose uti-
lized for the phase II portion of the study was 
determined from safety information collected 
during the escalation phase (including safety 
beyond the cycle 1).
The maximum dose delay allowed for each drug 
was 21 days. Treatment continued for up to 
12 months until PD, unacceptable toxicity or 
withdrawal of consent. After 12 months, those 
participants receiving clinical benefit were allowed 
to continue receiving treatment after sponsor 
approval.
Study objectives
The primary endpoint was 12-week CNS ORR 
and included all eligible participants (phase Ib/II) 
who completed four cycles and underwent brain 
magnetic resonance imaging (MRI) at 12 weeks. 
Secondary endpoints were evaluated in all 
patients who received at least one dose of study 
medication and included safety, PFS, OS, best 
CNS ORR, and extra-CNS ORR.
Study assessments
Participants were evaluated by clinical examina-
tion and laboratory tests at baseline and every 
3 weeks.
CNS response was evaluated per a modified 
response evaluation criteria in solid tumors 
(RECIST) version 1.123 that allowed the selec-
tion of up to five target lesions in the brain. MRI 
of the brain was performed every 6 weeks through 
cycle 6, then every 9 weeks. Response was meas-
ured by one central radiology reviewer. Clinical 
neurological assessments using a Neurological 
Signs and Symptoms (NSS) worksheet were done 
every time a brain MRI was performed.8 CNS 
complete response (CR) required complete dis-
appearance of all enhancing measurable and non-
measurable CNS disease sustained at least 
4 weeks, no new lesions, stable-to-improved NSS, 
no progression of extra-CNS disease, and no cor-
ticosteroid therapy. CNS PR was defined as 30% 
decrease in the sum of diameters of target lesions 
for at least 4 weeks (with confirmatory MRI 
administered at 4 weeks), no new lesions, stable-
to-improved NSS, no progression of extra-CNS 
disease, with the patient on a stable or lower dose 
of corticosteroid therapy compared with baseline. 
PD included any of the following: new CNS 
lesions, progression of CNS lesions, tumor-
related increase in steroid dose compared with 
baseline or best response, new or worsening 
tumor-related NSS, or progression of extra-CNS 
disease. Stable disease required there to be no 
CR, PR nor PD and stable or lower dose of ster-
oids compared with baseline with stable-to-
improved NSS.
Radiographic assessment of extra-CNS response 
with MRI or computed tomography (CT) scans 
(or proton emission tomography/CT) of the chest 
and abdomen was conducted at screening and 
every 9 weeks until the end of treatment. Other 
scans (mammogram, bone scan) were also used 
for per investigator discretion. The extra-CNS 
ORR was evaluated using RECIST version 1.1.23 
Safety and tolerability were assessed at each study 
visit according to the NIH-NCI CTCAE version 
4.03.
Statistical analysis
The primary endpoint was a 12-week CNS 
ORR. Standard systemic therapy was associated 
with a CNS response rate of 20% (P0).8 
Assuming an ORR for investigational combina-
tion was 35% (P1), 47 participants would be 
required to detect a difference with 80% power, 
and a 0.05 significance level using a one-sided 
Chi-square test. Due to slow accrual and 
restricted funding, the study closed after enroll-
ment of 19 participants. Statistical analysis based 
on an intention-to-treat (ITT) approach was 
performed at the end of the study. Under this 
approach, analysis for the primary endpoint was 
based on all eligible participants who underwent 
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an MRI at the 12-week timepoint and was esti-
mated with a 95% confidence interval (CI). 
Participants’ baseline clinical characteristics 
were summarized using descriptive statistics. 
Safety analysis included all participants who 
enrolled and received at least one dose of study 
treatment. AEs were tabulated by body system, 
severity and relation with study treatment. 
Common toxicities (experienced by ⩾10% of 
participants) were also identified. PFS and OS 
distributions were estimated using a Kaplan–
Meier product limit method and survival curves 
for PFS and OS were plotted. Median PFS, 
median OS (and corresponding 95% CI) were 
obtained. Fisher’s exact tests were performed to 
evaluate the association between CNS ORR and 
HR status, with prior brain radiation [stereotac-
tic radiosurgery (SRS) and whole brain irradia-
tion (WBI)] or prior brain surgery, with prior 
lapatinib or prior capecitabine. Similarly, log-
rank tests were used to assess the association 
between PFS and these variables. For all statisti-
cal investigations, tests for significance were 
two-tailed. A p-value less than the 0.05 signifi-
cance level was considered to be statistically sig-
nificant. All statistical analyses were carried out 
using SAS software version 9.4 (SAS Institute 
Inc., Cary, NC, USA).
Results
Participant characteristics
From 7 June 2013 to 4 January 2016, 21 partici-
pants were screened and 19 participants were 
enrolled and treated with at least one dose of 
study drug (10 in phase Ib, 9 in phase II) at 11 
centers in the US (Figure 1). Baseline participant 
characteristics are shown in Table 1 and patient 
disposition and prior treatments received are 
shown in Table 2. All participants were evaluable 
for safety and secondary outcome measures. 
Participants had received a median of 2.5 (0–11) 
prior systemic therapies for MBC including lapa-
tinib or capecitabine in 14 (74%); 3 had prior 
lapatinib but not capecitabine, 2 had prior 
capecitabine but not lapatinib, and 9 had prior 
capecitabine and lapatinib. Additionally, 12 par-
ticipants (63%) had prior CNS radiotherapy or 
surgery and radiation (9 had radiation only and 3 
had both surgery and radiation). Of the 12 
patients who had prior CNS radiation, 2 had ste-
reotactic radiosurgery only, 5 had whole brain 
radiation only and 5 had both whole brain radia-
tion and stereotactic radiosurgery (see Table 2). 
At baseline, eight participants (63%) had meas-
urable extra-CNS metastatic disease.
Phase Ib dose-escalation phase
A total of 10 study participants were enrolled and 
treated in the dose-escalation phase of the trial: 3 
in cohort 1, 4 in cohort 2, and 3 in cohort 3. Of 
the participants enrolled in cohort 2, one did not 
receive the study treatment per protocol, thus 
after receiving Data Safety Monitoring Board 
approval, a fourth participant was enrolled in this 
cohort. No DLTs were observed in any of the 
three cohorts.
In cohort 3, one participant experienced a serious 
adverse event (SAE) of grade 3 cellulitis, which 
was not a DLT-based on the protocol definition, 
given its onset outside the observation window for 
DLTs (during cycle 1). The MTD was established 
at the cohort 3 dose level. However, given the need 
for dose reductions due to toxicity after cycle 1 in 
cohort 3, cohort 2 dose levels were used in the 
phase II expansion portion of the study. A total of 
nine participants were enrolled in the phase II por-
tion and received capecitabine (750 mg/m2), 
everolimus (10 mg) and lapatinib (1000 mg).
Safety
The safety results are summarized in Table 3. 
SAEs were reported in seven (36.8%) partici-
pants, including radiation necrosis, catheter-
related infection, cellulitis, confusion, 
dehydration, hyperglycemia, mucositis, pleural 
effusion, pneumonia (n = 2), pulmonary embo-
lism, and weakness/lethargy. Overall there were 
12 grade 3/4 treatment-emergent adverse events 
(TEAEs), all of which were grade 3 with the 
exception of one grade 4 hypokalemia and one 
grade 4 fever. The most common grade 3/4 
TEAEs were oral mucositis (n = 3, 16%), hypoka-
lemia, fatigue, and diarrhea (n = 2, 11% for each). 
Prophylactic use of steroid mouthwash was not 
required nor was it used by any patient in this trial 
as this study predated the standard use of prophy-
lactic mouthwash. One patient had grade 3 hyper-
glycemia. She was taking dexamethasone 2 mg 
daily for her history of seizures and dizziness 
which, in addition to the known effects of everoli-
mus on glucose metabolism, may have contrib-
uted to this event. No deaths occurred on 
treatment. Overall, three deaths occurred during 
the 30-day follow up after the last dose of study 
drugs due to PD.
S Hurvitz, R Singh et al.
journals.sagepub.com/home/tam 5
Primary objective outcomes
A total of 11 eligible participants completed four 
cycles of treatment, underwent brain MRI at 12 
weeks and were evaluable for the primary effi-
cacy outcome of the 12-week CNS ORR. Of 
these, three participants (27%) had previously 
received lapatinib and capecitabine, three (27%) 
had received lapatinib but no prior capecitabine, 
and two (18%) had received capecitabine but no 
prior lapatinib (see Table 4).
The 12-week CNS ORR was 27% with three 
participants showing a PR at 12 weeks (95% CI, 
3.6–41.4). All responding patients were started 
with the same drug doses (capecitabine 750 mg/
m2, everolimus 10 mg and lapatinib 1000 mg). 
One of these participants had advanced estrogen 
and progesterone receptor (ER/PgR)-positive 
disease and had received two previous lines of 
systemic treatment in the metastatic setting, 
including lapatinib as well as CNS SRS and 
WBI. She came off the treatment for noncompli-
ance after 19 cycles. The second participant had 
no prior CNS radiation and four previous lines 
of therapy for metastatic disease (including 
capecitabine). She came off the treatment for 
CNS progression after 13 cycles. The third par-
ticipant had prior surgical resection of CNS 
metastases and three previous lines of therapy in 
the metastatic setting (including lapatinib). She 
came off the study after 30 cycles due to CNS 
progression. Both the second and third partici-
pants had HR-negative disease with measurable 
extra-CNS disease at baseline, and both achieved 
PR in their extra-CNS ORR. Images from the 
baseline and 12-week MRIs from the three 
patients who achieved a response are shown in 
Figure 2.
Table 1. Baseline patient characteristics (n = 19).
Age (mean) 58.5
Hormone receptor status  
 ER−/PgR− 7 (36.8%)
 ER+/PgR− 5 (26.3%)
 ER−/PgR+ 1 (5.2%)
 ER+/PgR+ 6 (31.6%)
Previous therapy for metastatic disease  
 No prior therapy 2 (10.5%)
 1 line of treatment 1 (5.2%)
 2 lines of treatment 7 (36.8%)
 ⩾3 lines of treatment 9 (47.4%)
 Median no. of lines 2.5 (0–11)
ECOG performance status  
 0 4 (21.1%)
 1 12 (63.2%)
 2 3 (15.8%)
Median # of CNS progressions prior to study (range) 2 (0–5)
Measurable extra-CNS disease at baseline 8 (42.1%)
CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor;
PgR, progesterone receptor.
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Secondary objective outcomes
A total of 19 participants were eligible for evalua-
tion of PFS and OS. Overall, three participants 
were censored from the PFS analysis: two with-
drew consent and one was noncompliant. The 
median PFS was 6.2 months (95% CI, 3.2–9.1) 
and median OS was 24.2 months (95% CI, 6.2–
25.4) (Table 5).
CNS ORR was defined as the best response 
attained at any time on study. In addition to the 
three PRs noted, one additional participant 
attained a CNS PR and one attained a CNS CR 
after 12 weeks. Thus, the CNS ORR (ITT) was 
26% (5/19). Of 19 patients, 9 (47%) participants 
had stable CNS disease as their best response. 
One participant (not counted as having a 
response) was found to be ineligible after enroll-
ment (she received CNS radiation to the target 
brain lesion without progression in the CNS prior 
to enrollment). Accounting for this, the CNS 
ORR in eligible participants is 28% (5/18). One 
participant with HR+ disease with stable disease 
at the 12-week timepoint achieved a CNS PR at 
cycle 6. Prior treatment included four lines of sys-
temic therapy including lapatinib and capecit-
abine as well as whole brain and gamma knife 
radiation. Her disease progressed at cycle 9. 
Another participant with HR+ breast cancer pre-
viously treated with lapatinib as well as SRS and 
WBI who had stable disease at 12 weeks went to 
surgery at cycle 13 for possible progression of 
CNS metastasis. Resection pathology revealed no 
viable tumor, only necrosis. Thus, she achieved a 
CR. She came off the study at cycle 19 for non-
compliance (without PD).
The extra-CNS ORR (ITT) was 10.6% (2/19). 
Both responses were partial and both participants 
also achieved a PR in the CNS. Of 19 partici-
pants, 8 had measurable extra-CNS disease at 
baseline. Of these, two (25.0%) achieved a PR, 
five (63%) had stable disease, and one participant 
(13%) had PD as their best extra-cranial response.
Table 2. Patient disposition and prior treatment history.
Phase Ib
(n = 10)
Phase II
(n = 9)
Total
(n = 19)
Off treatment reason  
Disease progression 9 6 15
• CNS 6 5 11
• Extra-CNS 2 1 3
• Both 1 0 1
Consent withdrawal 0 2 2
Noncompliance 1 1 2
Prior treatment history  
Prior lapatinib/capecitabine  
• Lapatinib (no capecitabine) 1 2 3
• Capecitabine (no lapatinib) 2 0 2
• Both 5 4 9
Prior CNS radiation/surgery  
• Rad only (SRS/WB/both) (0/3/1) (1/1/3) 9
• Surgery only (no radiation) 0 0 0
• Both radiation and surgery (SRS/WB/both) (1/1/1) (0/0/0) 3
CNS, central nervous system; SRS, stereotactic radio surgery; WB, whole brain.
S Hurvitz, R Singh et al.
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No significant associations were found when 
comparing CNS ORR by HR status, prior brain 
radiation or surgery, or with prior lapatinib or 
prior capecitabine. Similarly, no significant asso-
ciations were found using these comparisons for 
PFS (all p-values >0.05).
Discussion
There are limited therapeutic options for patients 
with trastuzumab-refractory, HER2+ breast can-
cer who develop CNS disease after cranial sur-
gery/radiotherapy. As the survival of these patients 
continues to improve, the need for effective sal-
vage therapies will increase.24 While consensus 
guidelines from the American Society of Clinical 
Oncology for treating HER2+ CNS metastases 
include surgical resection with postoperative radi-
ation, SRS, and WBI,25 trials that evaluate novel 
systemic therapies and innovative treatment com-
binations are desperately needed.
Several studies have been conducted to evaluate 
the activity of lapatinib plus capecitabine for 
HER2+ CNS metastases.8,26–31 Responses were 
reported in two clinical trials evaluating lapatinib 
Table 4. Primary endpoint CNS objective response rate at 12 weeks*.
Phase Ib (n = 5) Phase II (n = 6) Total (n = 11)
Objective response rate, n (%) 2 (40.0%) 1 (16.7%) 3 (27.3%)
 Complete response 0 0 0
 Partial response 2 1 3
* Evaluable population included eligible patients who received four cycles of treatment and underwent imaging of the brain 
at week 12.
CNS, central nervous system.
Table 5. Secondary endpoints.
Phase Ib (n = 10) Phase II (n = 9) Total (n = 19)
CNS objective response rate, n (%)a 3 (30) 2 (22) 5 (26)
 Complete response 0 1 (11) 1 (6)
 Partial response 3 (30)b 1 (11) 4 (22)
 Stable disease 3 (30) 6 (67) 9 (47)
Clinical benefit rate, n (%) 4 (40) 4 (44) 8 (42)
 Phase Ib (n = 4) Phase II (n = 4) Total (n = 8)
Extra-CNS objective response rate, n (%)c 1 (25) 1 (25) 2 (25)
 Complete response 0 0 0
 Partial response 1 (25) 1 (25) 2 (25)
 Stable disease 2 (50) 3 (75) 5 (63)
Median PFS, months (95% CI) 4.6 (1.2, 9.1) 6.3 (0.5, 20.9) 6.2 (3.2, 9.1)
Median OS, months (95%) 12.1 (5.2, 25.4) NR (2.1, NR) 24.2 (6.2, 25.4)
a CNS ORR, all 19 treated patients included in intent to treat analysis, however 1 patient was later found to be ineligible as 
she had received CNS radiation to the sole target brain lesion. Her results are not included as a response.
bOne patient achieved response after 12 weeks and was not included in primary endpoint of CNS ORR at week 12.
cOnly patients with measurable extra-CNS lesions at screening were included.
CI, confidence interval; CNS, central nervous system; NR, not reached; ORR, objective response rate; OS, overall survival; 
PFS, progression-free survival.
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plus capecitabine that enrolled patients who were 
not heavily pretreated. A phase II trial reported 
an ORR of 33.3% (7/21 all PR) and median PFS 
of 5.5 months in patients with HER2+ MBC with 
CNS involvement previously treated with trastu-
zumab.26 Cranial radiation had been given to 16 
of the 21 participants prior to enrollment. The 
ORR was 31.2% (5/16) in patients who received 
prior cranial therapy and 40% (2/5) in patients 
who were receiving first-line treatment. Another 
phase II trial investigated lapatinib plus capecit-
abine versus lapatinib plus topotecan for patients 
with HER2+ BCBM and demonstrated an ORR 
of 38% in the lapatinib plus capecitabine arm.28 
In the phase II LANDSCAPE study, 65.9% 
(29/44) of the patients achieved a PR with lapat-
inib and capecitabine for their previously 
untreated brain metastases.29 All three studies 
restricted enrollment to patients with no previous 
exposure to lapatinib or capecitabine.
Lapatinib plus capecitabine has also been evalu-
ated in more heavily pretreated patients in a study 
led by Lin and colleagues. In this study, patients 
with BCBM whose disease progressed on lapatinib 
(n = 50)8 were allowed to continue on the study 
and add capecitabine. This regimen was associated 
with a 20% CNS ORR (all PR) and a median PFS 
of 3.65 months. In contrast, our study allowed 
patients to enroll who had previously received 
lapatinib or capecitabine. The majority of our 
patients had previously received capecitabine 
(n = 11, 58%) or lapatinib (n = 12, 63%).
Preclinical studies show that the PI3K pathway is 
uniquely active in BCBM, thus inhibition of this 
pathway represents a promising therapeutic 
option for these patients. Specifically, inhibition 
of PI3K and mTORC1 in patient-derived 
xenografts of HER2+ BCBM resulted in marked 
tumor regression mediated by significant reduc-
tions in p-S6RP and p-4EBP1 and significant 
decreases in Ki67 staining.32,33 A phase II study 
investigating the treatment of HER2-positive, 
progressive BCBM with everolimus, vinorelbine, 
and trastuzumab, reported a CNS ORR of only 
4% but an OS of 12.2 months with a 27% clinical 
benefit rate at 6 months (ClinicalTrials.gov iden-
tifier NCT01305941).34
To our knowledge, ours is the first prospective 
study reported to evaluate the combination of 
lapatinib and capecitabine plus everolimus for 
BCBM. Our study revealed that this regimen is 
generally well tolerated in patients and demon-
strates clear evidence of antitumor activity in very 
heavily pretreated patients with HER2+ BCBM 
with a CNS ORR of 27% at 12 weeks and a PFS 
of 6.2 months. Interestingly, two responding 
patients had previously been treated with lapat-
inib and one had previously received capecit-
abine. Moreover, this regimen seems to have a 
comparable observed effect outside the CNS.
One strength of this study is the utilization of a 
single radiologist reviewer of all MRI scans, thus 
CNS ORR was based on central assessment. This 
study had several limitations. First, accrual goals 
were not met, resulting in a small sample size in 
the phase II portion. Second, the lack of a control 
arm precludes a comparison from being made to 
other options commonly used for progressing 
CNS metastases, namely capecitabine and lapat-
inib. In addition, prior radiotherapy or surgical 
treatment may have influenced the observed 
response to therapy by altering the permeability 
of the blood–brain barrier or otherwise affecting 
the tumor microenvironment. That said, other 
Figure 1. Consort diagram.
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Figure 2. Magnetic resonance imaging showing partial response in three patients at the 12-week timepoint. 
Left panel: baseline; right panel: 12 weeks after therapy.
All patients initiated therapy with capecitabine 750 mg/m2, everolimus 10 mg and lapatinib 1000 mg.
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studies that included patients who had not had 
local therapy yielded higher CNS ORR.29,30 This 
study would have been strengthened by inclusion 
of a patient-reported quality of life metric. Lastly, 
there was variability regarding prior exposure to 
lapatinib or capecitabine among our patient pop-
ulation which made it challenging to fully ascer-
tain the effect of everolimus on treatment efficacy. 
While one of the patients who achieved CNS PR 
at 12 weeks had been treated with both lapatinib 
and capecitabine, we cannot be certain that the 
other patients who showed a response was due 
entirely to everolimus, as they were treated with 
two new drugs.
Conclusion
In summary, the novel triplet therapy combina-
tion of lapatinib, everolimus, and capecitabine 
has been shown to be well tolerated with regres-
sion of BCBM in over a quarter of patients with 
trastuzumab-refractory, heavily pretreated dis-
ease. While everolimus shows promising activity 
in the CNS, further studies are needed to better 
understand its role in CNS metastases.
Acknowledgements
We gratefully acknowledge Sadia Altaf and Zeiba 
Qidwai for their administrative support.
The protocol and datasets used and analyzed dur-
ing the current study are available from the cor-
responding author on reasonable request.
Funding
Industry support for this investigator-initiated 
trial was supplied by Glaxo-Smith-Kline and 
Novartis. Both companies reviewed the manu-
script prior to submission. Dr Hurvitz receives 
support from NCI/NIH CA016042 as well as the 
Marni Levine Memorial Research Award.
Conflict of interest statement
SH: Research Funding: Amgen, Ambryx, 
Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, 
Genentech/Roche, GSK, Immunomedics, Lilly, 
Macrogenics, Medivation, Merrimack, Novartis, 
Cascadian, OBI Pharma, Pfizer, Pieris, PUMA, 
Seattle Genetics, Dignitana (In addition to 
research funding) “Chief Medical Officer (unpaid 
position) for TRIO-U; AM: Employment: 
Genentech, stock ownership: Roche, research 
funding: Oncothyreon, EMD-Serono; JM: 
research funding: BMS; BD research funding: 
Astra Zeneca, Novartis, Syndax, Halozyme, 
Roche/Genentech, Takeda, Armo, BMS (online); 
RC: stock ownership-Merck, consulting: 
Novartis, Pfizer; AC: Consulting: Myriad, 
Biotheranostics; Research Funding: Cascadian 
Therapeutics, Pfizer, Novartis, PUMA 
Biotechnology; IS: Employment: Tower Imaging 
Medical Group, Consulting: Nektar; XW, BA, 
EH, RD, JT, IM, RS: None; DC: Stock: Abbvie, 
Gilead Sciences, Exelexis, Seattle Genetics, 
Loso, Tesaro, Exact Sciences, Consulting: 
Counsyl; DJS: Board Member: BioMarin, Stock 
Ownership: Pfizer, BioMarin, Amgen, Cascadian 
Therapeutics, Seattle Genetics, Consultant/Ad 
Board/Honoraria: Pfizer, Lilly, Novartis, 
Contracted Research: Pfizer, Syndax, Novartis, 
Lilly; DM: None; BMS: JB Research Funding.
References
 1. Romond EH, Perez EA, Bryant J, et al. 
Trastuzumab plus adjuvant chemotherapy for 
operable HER2-positive breast cancer. N Engl J 
Med 2005; 353: 1673–1684.
 2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, 
et al. Trastuzumab after adjuvant chemotherapy 
in HER2-positive breast cancer. N Engl J Med 
2005; 353: 1659–1672.
 3. Slamon D, Eiermann W, Robert N, et al. 
Adjuvant trastuzumab in HER2-positive breast 
cancer. N Engl J Med 2011; 365: 1273–1283.
 4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use 
of chemotherapy plus a monoclonal antibody 
against HER2 for metastatic breast cancer that 
overexpresses HER2. N Engl J Med 2001; 344: 
783–792.
 5. Marty M, Cognetti F, Maraninchi D, et al. 
Randomized phase II trial of the efficacy and 
safety of trastuzumab combined with docetaxel 
in patients with human epidermal growth factor 
receptor 2-positive metastatic breast cancer 
administered as first-line treatment: the M77001 
study group. J Clin Oncol 2005; 23: 4265–4274.
 6. Bendell JC, Domchek SM, Burstein HJ, et al. 
Central nervous system metastases in women who 
receive trastuzumab-based therapy for metastatic 
breast carcinoma. Cancer 2003; 97: 2972–2977.
 7. Musolino A, Ciccolallo L, Panebianco M, et al. 
Multifactorial central nervous system recurrence 
susceptibility in patients with HER2-positive 
breast cancer: epidemiological and clinical data 
from a population-based cancer registry study. 
Cancer 2011; 117: 1837–1846.
 8. Lin NU, Dieras V, Paul D, et al. Multicenter 
phase II study of lapatinib in patients with brain 
Therapeutic Advances in Medical Oncology 10
12 journals.sagepub.com/home/tam
metastases from HER2-positive breast cancer. 
Clin Cancer Res 2009; 15: 1452–1459.
 9. Boulay A, Rudloff J, Ye J, et al. Dual inhibition 
of mTOR and estrogen receptor signaling in vitro 
induces cell death in models of breast cancer. Clin 
Cancer Res 2005; 11: 5319–5328.
 10. Boulay A, Zumstein-Mecker S, Stephan C, et al. 
Antitumor efficacy of intermittent treatment 
schedules with the rapamycin derivative 
RAD001 correlates with prolonged inactivation 
of ribosomal protein S6 kinase 1 in peripheral 
blood mononuclear cells. Cancer Res 2004; 64: 
252–261.
 11. Seeliger H, Guba M, Kleespies A, et al. Role of 
mTOR in solid tumor systems: a therapeutical 
target against primary tumor growth, metastases, 
and angiogenesis. Cancer Metastasis Rev 2007; 26: 
611–621.
 12. Beuvink I, Boulay A, Fumagalli S, et al. The 
mTOR inhibitor RAD001 sensitizes tumor cells 
to DNA-damaged induced apoptosis through 
inhibition of p21 translation. Cell 2005; 120: 
747–759.
 13. Baselga J, Campone M, Piccart M, et al. 
Everolimus in postmenopausal hormone-
receptor-positive advanced breast cancer. New 
Engl J Med 2012; 366: 520–529.
 14. Hurvitz SA, Kalous O, Conklin D, et al. In vitro 
activity of the mTOR inhibitor everolimus, in a 
large panel of breast cancer cell lines and analysis 
for predictors of response. Breast Cancer Res Treat 
2015; 149: 669–680.
 15. Andre F, O’Regan R, Ozguroglu M, et al. 
Everolimus for women with trastuzumab-
resistant, HER2-positive, advanced breast cancer 
(BOLERO-3): a randomised, double-blind, 
placebo-controlled phase 3 trial. Lancet Oncol 
2014; 15: 580–591.
 16. Meikle L, Pollizzi K, Egnor A, et al. Response 
of a neuronal model of tuberous sclerosis to 
mammalian target of rapamycin (mTOR) 
inhibitors: Effects on mTORC1 and Akt signaling 
lead to improved survival and function. J Neurosci 
2008; 28: 5422–5432.
 17. Gadgeel SM, Lew DL, Synold TW, et al. Phase I 
study evaluating the combination of lapatinib (a 
Her2/Neu and EGFR inhibitor) and everolimus 
(an mTOR inhibitor) in patients with advanced 
cancers: South West Oncology Group (SWOG) 
Study S0528. Cancer Chemother Pharmacol 2013; 
72: 1089–1096.
 18. Deenen MJ, Klumpen HJ, Richel DJ, et al. Phase 
I and pharmacokinetic study of capecitabine and 
the oral mTOR inhibitor everolimus in patients 
with advanced solid malignancies. Invest New 
Drug 2012; 30: 1557–1565.
 19. Lim T, Lee J, Lee DJ, et al. Phase I trial of 
capecitabine plus everolimus (RAD001) in 
patients with previously treated metastatic  
gastric cancer. Cancer Chemoth Pharm 2011;  
68: 255–262.
 20. Wolff AC, Hammond MEH, Schwartz JN, 
et al. American Society of Clinical Oncology/
College of American Pathologists guideline 
recommendations for human epidermal growth 
factor receptor 2 testing in breast cancer. Arch 
Pathol Lab Med 2007; 131: 18–43.
 21. Health UDo, Services H. Common terminology 
criteria for adverse events v4. 03, 2010.
 22. Oken MM, Creech RH, Tormey DC, et al. 
Toxicity and response criteria of the eastern-
cooperative-oncology-group. Am J Clin Oncol-
Canc 1982; 5: 649–655.
 23. Eisenhauer EA and Verweij J.New response 
evaluation criteria in solid tumors: RECIST 
guideline version 1.1. EJC Suppl 2009; 45: 
228–247.
 24. Kirsch DG, Ledezma CJ, Mathews CS, et al. 
Survival after brain metastases from breast cancer 
in the trastuzumab era. J Clin Oncol 2005; 23: 
2114–2116; author reply 2116–2117.
 25. Ramakrishna N, Temin S, Chandarlapaty S, et al. 
Recommendations on disease management for 
patients with advanced human epidermal growth 
factor receptor 2-positive breast cancer and 
brain metastases: American Society of Clinical 
Oncology clinical practice guideline. J Clin Oncol 
2014; 32: 2100–2108.
 26. Sutherland S, Ashley S, Miles D, et al. Treatment 
of HER2-positive metastatic breast cancer 
with lapatinib and capecitabine in the lapatinib 
expanded access programme, including efficacy in 
brain metastases–the UK experience. Br J Cancer 
2010; 102: 995–1002.
 27. Oktay E, Yersal O, Meydan N, et al. Nearly 
complete response of brain metastases from 
HER2 overexpressing breast cancer with 
lapatinib and capecitabine after whole brain 
irradiation. Case Rep Oncol Med 2013; 2013: 
234391.
 28. Lin NU, Eierman W, Greil R, et al. Randomized 
phase II study of lapatinib plus capecitabine 
or lapatinib plus topotecan for patients with 
HER2-positive breast cancer brain metastases. J 
Neurooncol 2011; 105: 613–620.
 29. Bachelot T, Romieu G, Campone M, et al. 
Lapatinib plus capecitabine in patients with 
S Hurvitz, R Singh et al.
journals.sagepub.com/home/tam 13
previously untreated brain metastases from 
HER2-positive metastatic breast cancer 
(LANDSCAPE): a single-group phase 2 study. 
Lancet Oncol 2013; 14: 64–71.
 30. Shawky H and Tawfik H. All-oral combination of 
lapatinib and capecitabine in patients with brain 
metastases from HER2-positive breast cancer–a 
phase II study. J Egypt Natl Canc Inst 2014; 26: 
187–194.
 31. Morikawa A, Peereboom DM, Thorsheim 
HR, et al. Capecitabine and lapatinib uptake 
in surgically resected brain metastases from 
metastatic breast cancer patients: a prospective 
study. Neuro Oncol 2015; 17: 289–295.
 32. Adamo B, Deal AM, Burrows E, et al. 
Phosphatidylinositol 3-kinase pathway activation 
in breast cancer brain metastases. Breast Cancer 
Res 2011; 13: R125.
 33. Ni J, Ramkissoon SH, Xie S, et al. Combination 
inhibition of PI3K and mTORC1 yields durable 
remissions in mice bearing orthotopic patient-
derived xenografts of HER2-positive breast cancer 
brain metastases. Nat Med 2016; 22: 723–726.
 34. Anders CK, Deal AM, Van Swearingen AED, 
et al. Phase II study of everolimus, trastuzumab, 
and vinorelbine for HER2+ breast cancer 
brain metastases (BCBM). J Clin Oncol 2017; 
35(Suppl.): abstract 1011.
Visit SAGE journals online 
journals.sagepub.com/
home/tam
SAGE journals
